Low Dose Naltrexone
LDN
Low Dose Naltrexone (LDN) is a longevity & bioregulators research compound. At 50mg naltrexone is a straightforward opioid antagonist. At 1.5–4.5mg the proposed mechanism is completely different — transient receptor blockade causing rebound endorphin upregulation, plus TLR4 antagonism on microglia reducing neuroinflammation.
Low Dose Naltrexone quick facts
| Reported research dose | 1.5–4.5mg at bedtime |
| Route | Oral |
| Frequency | 1x · Nightly |
| Half-life | ~4 hours for the parent |
| Forms | Oral |
| Evidence level | Small positive trials in fibromyalgia and Crohn's; the wider claims outrun the data |
Cheap, well tolerated and genuinely interesting mechanistically. But the enthusiasm has run a long way past the evidence — the trials are small, mostly single-center, and the list of conditions it's marketed for is far longer than the list it's been tested in. ⚠️ Blocks opioid analgesia. Must be compounded; standard tablets are 50mg.
How Low Dose Naltrexone works
At 50mg naltrexone is a straightforward opioid antagonist. At 1.5–4.5mg the proposed mechanism is completely different — transient receptor blockade causing rebound endorphin upregulation, plus TLR4 antagonism on microglia reducing neuroinflammation.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Low Dose Naltrexone
Buy Low Dose Naltrexone at AlgoRx →The evidence for Low Dose Naltrexone
Graded by what exists behind each claim.
✅ Clinically validated
- Naltrexone itself is FDA-approved at 50 mg for opioid and alcohol dependence, with solid trial data. Low-dose use at 1–4.5 mg is entirely off-label and is a different proposition.
- Small randomized trials exist and are genuinely encouraging in a few conditions — fibromyalgia (small crossover trials reporting reduced pain) and Crohn's disease (small pilots reporting endoscopic improvement). A Cochrane review of LDN in Crohn's concluded the evidence was insufficient.
- Small, single-center, short. This is a promising signal that has never been funded to a definitive trial, largely because the drug is generic and nobody stands to profit from the answer.
📊 Correlative data
- Substantial real-world use in chronic pain and autoimmune conditions, largely driven by patient communities and a small number of prescribing clinicians. Excellent tolerability at these doses — vivid dreams and initial sleep disturbance are the common reports.
- The interaction that matters is absolute: it blocks opioid analgesia, so it is incompatible with opioid pain management and dangerous around surgery if not disclosed.
🧪 Theoretical / extrapolated
- Two proposed mechanisms, and they are different. First, transient opioid receptor blockade causes rebound upregulation of endogenous endorphins and receptors — which is why the timing of the dose matters and why the dose has to be low enough to wear off.
- Second, and probably more important for the inflammatory conditions: naltrexone antagonizes Toll-like receptor 4 on microglia, damping neuroinflammation. This mechanism is not opioid-mediated at all — it works with the non-opioid stereoisomer — which is why it can plausibly help conditions that have nothing to do with endorphins.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Low Dose Naltrexone actually does
Low-dose naltrexone is not a low dose of a painkiller. It is a fraction of an opioid blocker, given to produce an effect the blocking dose does not produce — and there are two competing mechanistic accounts of how that could work. They are not variations on a theme; they involve different receptors on different cells, and only one of them requires the opioid system at all.
Account one: transient blockade, compensatory rebound. Naltrexone is a competitive antagonist at mu, kappa and delta opioid receptors. At 50 mg the blockade is near-complete and continuous. At 1.5 to 4.5 mg it is partial and, critically, brief — the card gives about 4 hours for the parent compound. The hypothesis is that a short interruption of endogenous opioid signaling provokes a compensatory increase in endorphin and enkephalin production and in receptor density, which outlasts the blockade. Under this account the short half-life is not a limitation, it is the mechanism: a long-acting formulation would produce continuous blockade and abolish the effect entirely. That is a genuinely unusual pharmacological claim and it makes a testable prediction about formulation.
Account two, and it has better evidence: this is not an opioid effect at all. Naltrexone antagonizes Toll-like receptor 4 on glial cells. TLR4 is an innate-immune pattern receptor, and on microglia its activation drives NF-kappaB-dependent release of inflammatory cytokines that sensitize pain pathways. Opioids interact with TLR4 in ways now reviewed as a field in their own right Gabr 2021, and naltrexone has a demonstrated immunometabolic modulatory role in microglial cells Kučić 2021.
The evidence that decides between the two is stereochemistry. Opioid receptors are strictly stereoselective: only the (−) enantiomer of naltrexone binds them. TLR4 is not stereoselective in this way, and the (+) enantiomer — which has no opioid activity whatsoever — retains glial activity. An effect that survives removal of all opioid binding cannot be an opioid effect. That single observation is why the glial account has largely displaced the rebound one in the serious literature Mustafa 2023.
Which makes low-dose naltrexone a neuroimmune drug rather than an analgesic, and reframes what it should be expected to do: not block pain transmission, but reduce the glial sensitization that amplifies it. Chronic pain and opioid pharmacology are increasingly understood through exactly that immune lens Mustafa 2023.
Cell, rodent, human — and where it stops
Step one, cells: real, and specific to this molecule. Naltrexone modulates microglial immunometabolism Kučić 2021 and the opioid-TLR4 interaction is characterized Gabr 2021.
Step two, the clinical literature before the definitive trial. A systematic review examined the clinical efficacy of low-dose naltrexone and its effect on putative pathophysiological mechanisms in fibromyalgia Partridge 2023, and a meta-analysis with trial sequential analysis pooled the randomized trials Vatvani 2024. Trial sequential analysis is the right tool and it is worth knowing why: it asks whether the accumulated sample size is large enough to have settled the question, or whether an apparently positive pooled result is the kind that appears and disappears as small trials accumulate.
Step three, the definitive trial — and it missed. The FINAL trial randomized 99 women with fibromyalgia, 49 to naltrexone 6 mg once daily and 50 to placebo, in a double-blind placebo-controlled design registered and published in advance Bruun 2021. Mean change in pain intensity was −1.3 points (95% CI −1.7 to −0.8) on naltrexone against −0.9 (−1.4 to −0.5) on placebo, p = 0.27 Due Bruun 2024.
Read that carefully, because it is the most honest paragraph on this page. Both groups improved. The drug group improved slightly more. The difference was not statistically significant and the confidence intervals overlap substantially. Adverse events occurred in 41 of 49 (84%) on naltrexone and 43 of 50 (86%) on placebo — which is the other informative number, because it says the drug is remarkably well tolerated and that side-effect reporting in this population is almost entirely non-specific.
Step four, what a null result of this size does and does not establish. Ninety-nine participants can exclude a large effect and cannot exclude a small one. A trial that misses its primary endpoint has not proven the drug useless; it has failed to demonstrate the effect it was designed to detect, and the difference between those two statements is where every honest discussion of low-dose naltrexone now lives.
Where the chain breaks. (1) Fibromyalgia is defined by symptoms with no objective diagnostic marker, so the trial's primary endpoint is a subjective scale with a large placebo response — visible directly in the −0.9 point placebo change Due Bruun 2024. (2) The glial mechanism Kučić 2021 predicts an effect on neuroinflammation, and no trial has measured neuroinflammation. (3) Doses in circulation range from 1.5 to 4.5 mg and the definitive trial used 6 mg; nobody has established a dose-response. (4) Every other indication low-dose naltrexone is used for — Crohn's disease, multiple sclerosis, long COVID, complex regional pain syndrome — has a far thinner evidence base than fibromyalgia, which is the one that has now had its definitive trial.
What would have to be true, and how you would know it was not
Three predictions. The first accepts the trial result, the second tests the mechanism the trial did not measure, and the third is the safety floor.
1. The honest efficacy prediction is a small effect or none. The definitive randomized trial found −1.3 against −0.9 points, p = 0.27 Due Bruun 2024. Anyone testing this on themselves should expect roughly what that trial found, and the way to avoid fooling yourself is a written 0–10 daily score for two weeks before starting and eight weeks after, scored before the day is over rather than reconstructed later. The placebo arm improved by nearly a point; a personal improvement of that size is exactly what would have happened anyway.
2. The mechanism prediction, which no trial has tested. If the drug works through TLR4 on glia Gabr 2021 Kučić 2021, systemic inflammatory signaling should shift. hs-CRP and TNF-alpha at baseline and 12 weeks, measured away from any acute illness. These are imperfect peripheral proxies for a central glial process and this page says so — but a fall in both, in somebody whose pain score also fell, is the only mechanistically coherent evidence an individual can generate, and a change in pain with no change in either is evidence the mechanism is not the explanation.
3. The safety measurement, which is short and non-negotiable. Naltrexone is hepatically metabolized and carried a hepatotoxicity warning at the 50 mg dose. A CMP for ALT, AST and bilirubin at baseline and 12 weeks. The other absolute check is not a blood test: any opioid taken with naltrexone on board will not work, and an opioid taken after naltrexone is stopped meets receptors that have been unoccupied. That is the sentence that matters most on this page and it belongs in the safety section below as well.
What nobody has tested yet
Four experiments nobody has run, and the first one is now the most important question in the field.
Nobody has run a dose-response study. The definitive trial used 6 mg Due Bruun 2024; almost all clinical practice uses 1.5 to 4.5 mg. If the rebound account is right, there is an optimum below which blockade is insufficient and above which it stops being transient — which would mean the trial tested a dose past the peak. A three-arm dose-ranging trial would answer it and would reframe the whole literature either way.
Nobody has measured neuroinflammation in a low-dose naltrexone trial. The mechanism is glial Kučić 2021 Mustafa 2023. Translocator-protein PET imaging can measure glial activation in living human brain, and it has been used in fibromyalgia. Nobody has combined it with a low-dose naltrexone trial, and that single study would convert a plausible mechanism into a measured one.
Nobody has tested the (+) enantiomer in humans. The stereochemistry argument says the glial effect does not need opioid binding Gabr 2021. (+)-naltrexone would deliver the proposed mechanism with none of the opioid-receptor consequences — no interference with analgesia, no precipitated withdrawal. It exists as a research chemical and has never been taken into a clinical trial.
Nobody has identified who responds. The pooled analyses Vatvani 2024 Partridge 2023 and the null trial Due Bruun 2024 all report averages. If a subgroup with measurable neuroinflammation responds while the rest do not, the average is guaranteed to look like this. A trial that stratifies on an inflammatory phenotype at entry is the design that could rescue this drug, and nobody has attempted it.
Low Dose Naltrexone — its own safety story, not its class's
Naltrexone is an approved medicine at 50 mg. Low-dose naltrexone is that drug compounded to a fraction of its licensed dose for unlicensed indications, and the class block above does not describe the risks that actually apply.
The opioid interaction is the one that can kill somebody, and it runs in both directions. Naltrexone blocks opioid receptors. Taking it while physically dependent on an opioid precipitates acute withdrawal within minutes, and even at low doses this can be severe. In the other direction, an opioid analgesic given while naltrexone is on board will not work — which is a serious problem in an emergency or after surgery. Anyone taking this compound must tell an anesthetist, a surgeon and an emergency clinician, and should not be the only person who knows.
Sleep disturbance and vivid dreams are the commonest complaints, which is unsurprising for a drug that interrupts endogenous opioid tone and is typically taken at night. In the randomized trial, adverse events occurred in 84% on drug and 86% on placebo Due Bruun 2024 — a difference of two percentage points, which is the cleanest possible statement that the tolerability concerns attributed to this drug are mostly not the drug.
Liver monitoring is reasonable rather than alarming. The 50 mg product carried a hepatotoxicity warning; the doses used here are a fraction of that, and a baseline and 12-week CMP is a proportionate response.
Compounding is a quality question. A 1.5 to 4.5 mg dose does not exist as a commercial product and must be compounded, which means content uniformity depends entirely on the pharmacy. A capsule that is supposed to contain 1% of a tablet is the kind of preparation where mixing quality matters most, and it is a real reason to use a compounding pharmacy rather than to divide tablets.
What this page will not do. Recommend a dose, or describe the definitive trial as anything other than what it was. It missed its primary endpoint Due Bruun 2024. The mechanism remains plausible and unmeasured, the drug is unusually well tolerated, and those three sentences together are the honest summary.
Sources read for this page
- Due Bruun K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatology 2024 · PMID 38258677
- Vatvani AD, et al. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean Journal of Pain 2024 · PMID 39344363
- Partridge S, et al. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon 2023 · PMID 37206027
- Gabr MM, et al. Interaction of Opioids with TLR4-Mechanisms and Ramifications. Cancers (Basel) 2021 · PMID 34771442
- Kučić N, et al. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. International Journal of Molecular Sciences 2021 · PMID 34445130
- Mustafa S, et al. One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology. Neuropharmacology 2023 · PMID 36775098
- Bruun KD, et al. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials 2021 · PMID 34781989
Low Dose Naltrexone — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- At its licensed dose naltrexone is a straightforward opioid antagonist. At a tenth of that the proposed mechanism is different: transient receptor blockade producing rebound endorphin upregulation, plus TLR4 antagonism on microglia reducing neuroinflammation.
- The prediction that matters is not a toxicity, it is an interaction: any opioid antagonist blocks opioid analgesia. If you need opioid pain relief — an accident, emergency surgery, a dental procedure — this is competing with it, and the treating team needs to know.
- Vivid dreams and disturbed sleep in the first weeks are consistent with the endorphin-rebound mechanism and are the most commonly reported effect.
What has actually been reported
- Sleep disturbance and vivid dreams, usually transient, and usually improved by moving the dose to the morning.
- Headache and mild GI upset. Overall it is very well tolerated at these doses, which is the main reason the interest persists despite the evidence gap.
- Randomized evidence exists in fibromyalgia and Crohn's disease and is small-scale and mixed. Enough to justify continued study; not enough to support the range of conditions it is offered for.
How to reduce the risk
Same mechanism as the prediction.
- Carry it on your medication list and tell any emergency team. That single act removes the only serious risk this drug has.
- Move the dose to the morning if dreams or insomnia appear — that fixes most of the tolerability problem.
- Set a decision point before starting: what you are measuring and when you will stop if it has not moved.
What it does to your bloodwork
A fact about the assay.
- Liver function (ALT/AST) at baseline is reasonable given the high-dose hepatotoxicity signal, even though it is not expected at these doses.
- There is no marker that tells you whether it is working. The endpoint is symptomatic, which means an honest trial needs a defined period and a defined thing you were measuring.
What it overlaps with
- Opioids, including codeine in over-the-counter combinations and loperamide at high dose. Check every analgesic.
Don't run this if
- Current opioid use of any kind, including for pain control. Precipitated withdrawal is the risk, and it is unpleasant and avoidable.
- Acute hepatitis or liver failure — the hepatotoxicity concern comes from much higher doses, but the caution stands.
- Anyone likely to need opioid analgesia imminently.
The honest unknown
- Almost everything about long-term use. There is no long-term safety or efficacy data at low dose in healthy people, no agreed mechanism confirmation in humans, and no standardized preparation — it is compounded, and compounding quality varies. Unproven is not ineffective; here it is unusually literal.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Low Dose Naltrexone — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Low Dose Naltrexone moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Low Dose Naltrexone in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Low Dose Naltrexone
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Low Dose Naltrexone — frequently asked questions
What is Low Dose Naltrexone?
Low Dose Naltrexone (LDN) is a longevity & bioregulators research compound. At 50mg naltrexone is a straightforward opioid antagonist. At 1.5–4.5mg the proposed mechanism is completely different — transient receptor blockade causing rebound endorphin upregulation, plus TLR4 antagonism on microglia reducing neuroinflammation.
Is the full Low Dose Naltrexone protocol on this page?
The reported research dose is on this page, along with how Low Dose Naltrexone works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Low Dose Naltrexone?
Low Dose Naltrexone has an approximate half-life of ~4 hours for the parent, which is part of what determines how often it's dosed.
What's the evidence behind Low Dose Naltrexone?
Current evidence level: Small positive trials in fibromyalgia and Crohn's; the wider claims outrun the data. Low Dose Naltrexone is offered for research purposes only and is not an approved medicine.
Low Dose Naltrexone inside a finished plan
One arm of 7 Protocol Blueprints, free to read in full.
What Low Dose Naltrexone is used for
Low Dose Naltrexone appears under 7 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Low Dose Naltrexone is the inflammation-resolution arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.